SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics - Quaterly Results

28 May 2025 Evaluate
The Turnover for the quarter ended March 2025 of Rs. 391.38 millions increase by 71.54% from Rs. 228.16 millions.The Net Loss for the quarter ended March 2025 is Rs. -142.92 millions as compared to Net Loss of Rs. -153.00 millions of corresponding quarter ended March 2024 Operating profit Margin for the quarter ended March 2025 improved to 58.03% as compared to -39.73% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 391.38 228.16 71.54 1424.48 1043.35 36.53 1424.48 1043.35 36.53
Other Income 23.92 0.09 26477.78 50.12 1.02 4813.73 50.12 1.02 4813.73
PBIDT 58.03 -39.73 -246.06 112.77 22.64 398.10 112.77 22.64 398.10
Interest 1.08 5.60 -80.71 26.92 19.32 39.34 26.92 19.32 39.34
PBDT -182.19 -133.06 36.92 -70.84 -84.41 -16.08 -70.84 -84.41 -16.08
Depreciation 38.99 26.61 46.52 123.00 106.73 15.24 123.00 106.73 15.24
PBT -221.18 -159.67 38.52 -193.84 -191.14 1.41 -193.84 -191.14 1.41
TAX -78.26 -6.67 1073.31 -46.26 26.18 -276.70 -46.26 26.18 -276.70
Deferred Tax -78.26 -6.67 1073.31 -46.26 26.18 -276.70 -46.26 26.18 -276.70
PAT -142.92 -153.00 -6.59 -147.58 -217.32 -32.09 -147.58 -217.32 -32.09
Equity 501.01 501.01 0.00 501.01 501.01 0.00 501.01 501.01 0.00
PBIDTM(%) 14.83 -17.41 -185.15 7.92 2.17 264.84 7.92 2.17 264.84

Lasa Supergenerics Share Price

8.02 0.13 (1.65%)
16-Apr-2026 12:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.40
Dr. Reddys Lab 1221.90
Cipla 1231.85
Zydus Lifesciences 935.70
Lupin 2300.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×